FOLH1 and Familial prostate cancer: To validate the recently published 5-point PRIMARY scoring system against a 5-point European Association of Nuclear Medicine (E-PSMA) Likert system for the detection of intraprostatic recurrence for patients undergoing [68Ga]Ga-PSMA-11 PET/CT who have previously received radiotherapy for prostate cancer as their primary treatment.